Welcome to our dedicated page for Contineum Therapeutics news (Ticker: CTNM), a resource for investors and traders seeking the latest updates and insights on Contineum Therapeutics stock.
Contineum Therapeutics, Inc. (CTNM) generates a steady flow of news as a clinical-stage biopharmaceutical company focused on novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications. News coverage for CTNM often centers on clinical trial milestones, topline data readouts and capital markets activity related to its lead programs PIPE-791 and PIPE-307.
Investors following CTNM news can expect updates on clinical development, including Phase 1b and Phase 2 trials in idiopathic pulmonary fibrosis, multiple sclerosis, chronic pain and major depressive disorder. The company has reported positive topline data from a Phase 1b PET trial of PIPE-791, topline results from the PIPE-307 VISTA Phase 2 trial in relapsing-remitting multiple sclerosis, and regular progress reports on planned global Phase 2 studies in idiopathic pulmonary fibrosis.
Contineum’s news flow also includes financial results and financing transactions. The company issues quarterly financial updates and has announced both at-the-market offerings and underwritten public offerings of Class A common stock, including an upsized public offering under an effective shelf registration statement. These items provide context on how Contineum funds its research and development plans.
Additional CTNM headlines cover investor conference participation, regulatory and trial design disclosures, and collaborations such as the global license and development agreement with Janssen Pharmaceutica NV for PIPE-307. For readers tracking the CTNM stock, this news page offers a centralized view of material events, clinical data announcements and corporate developments affecting Contineum Therapeutics.
Contineum Therapeutics (NASDAQ: CTNM) reported Q1 2026 results and affirmed clinical milestones. Cash, cash equivalents and marketable securities were $246.3 million as of March 31, 2026, supporting a projected cash runway through mid-2029. Net loss was $14.5 million.
Clinical highlights: positive topline Phase 1b PIPE-791 chronic pain data (April 30, 2026); PROPEL-IPF Phase 2 dosing initiated in Q1 2026 (26-week, ~324 patients; primary endpoint: change in absolute FVC mL); J&J’s Phase 2 PIPE-307 Moonlight-1 trial is recruiting with estimated completion in June 2026.
Contineum Therapeutics (NASDAQ: CTNM) announced inducement equity awards to two new non-executive employees under its 2026 Employment Inducement Equity Incentive Plan. Each employee received a non-qualified option for 51,000 Class A shares, granted on April 28 and April 30, 2026.
Each option vests over four years (25% after one year, then monthly over 36 months), has a ten-year term, and an exercise price equal to the closing price on the applicable grant date. Grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Contineum Therapeutics (NASDAQ: CTNM) reported positive topline data from an exploratory Phase 1b PIPE-791 trial in chronic osteoarthritis pain (COAP) and chronic low back pain (CLBP). The randomized, double-blind, placebo-controlled, 4-week crossover study (N=43) tested oral 10 mg once-daily dosing.
The trial met its primary endpoint for safety and tolerability, showed no serious adverse events, and produced consistent numerical improvements versus placebo on PI-NRS pain measures and responder rates, supporting further clinical evaluation of PIPE-791.
Contineum Therapeutics (NASDAQ: CTNM) announced an inducement grant on March 12, 2026: a non-qualified stock option to purchase 51,000 shares of Class A common stock to a new non-executive employee under the Company’s 2026 Employment Inducement Equity Incentive Plan.
The option uses the closing price on the grant date as its exercise price, vests over four years (25% at one year, then monthly over 36 months), and has a ten-year term, subject to plan and option agreement terms and continued service.
Contineum Therapeutics (NASDAQ: CTNM) reported fourth-quarter 2025 results and affirmed clinical milestones. Key updates: patient dosing started in PROPEL-IPF, a global Phase 2 trial of PIPE-791; topline Phase 1b PIPE-791 data expected Q2 2026; cash, cash equivalents and marketable securities of $262.9M as of Dec 31, 2025, and a projected cash runway into mid-2029. The company completed an upsized public offering, generating $93.0M net proceeds. R&D was $12.8M and net loss was $15.2M in Q4 2025.
Contineum Therapeutics (NASDAQ: CTNM) will present at the 2026 Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026 at 2:20 p.m. ET. The management fireside chat will be available via an audio webcast on the company’s Investors website, with a replay posted afterwards.
Contineum Therapeutics (NASDAQ: CTNM) announced an inducement award for a new non-executive employee on February 17, 2026. The Compensation Committee granted a non-qualified stock option to purchase 51,000 Class A shares under the company’s 2026 Employment Inducement Equity Incentive Plan.
The option’s exercise price equals the closing price on the Grant Date, vests over 4 years (25% at one year, then monthly over 36 months), and has a 10-year term, subject to the plan and an option agreement.
Contineum Therapeutics (NASDAQ: CTNM) announced an inducement award granted January 26, 2026 under its 2026 Employment Inducement Equity Incentive Plan.
The Compensation Committee awarded a non-qualified stock option for 23,000 Class A shares to a new non-executive employee; the option vests over 4 years, has a 10-year term, and an exercise price equal to the closing price on the grant date.
Contineum Therapeutics (Nasdaq: CTNM) priced an upsized public offering of 7,346,938 Class A shares at $12.25 per share, with gross proceeds expected to be about $90.0 million before fees.
The underwriters have a 30‑day option to buy up to an additional 1,102,040 shares. The offering is expected to close on December 15, 2025, subject to customary closing conditions.
Contineum Therapeutics (Nasdaq: CTNM) announced a proposed underwritten public offering of $75.0 million of Class A common stock, with a 30-day underwriter option to purchase up to an additional $11.25 million of shares, for potential gross proceeds of up to $86.25 million.
The offering is subject to market and other conditions and may not be completed. A related registration statement was filed May 14, 2025 and declared effective by the SEC on May 23, 2025. Goldman Sachs, Leerink Partners, Stifel, RBC Capital Markets and William Blair are joint book-running managers.